Tsunoda, Hiroyuki
Chugai Pharmaceutical Co., Ltd. (Japan)
3 papers on CoChatORCID 0009-0005-5016-4366
Most cited papers
- Verified
Reduced elimination of IgG antibodies by engineering the variable region
Igawa, T., Tsunoda, H., Tachibana, T., Maeda, A., Mimoto, F., Moriyama, C., Nanami, M., Sekimori, Y., Nabuchi, Y., Aso, Y., et al. (2010) · Protein Engineering Design and Selection
Monoclonal and Polyclonal Antibodies ResearchProtein purification and stability
Cited by 265
- Verified
Antibody design using LSTM based deep generative model from phage display library for affinity maturation
Saka, K., Kakuzaki, T., Metsugi, S., Kashiwagi, D., Yoshida, K., Wada, M., Tsunoda, H., & Teramoto, R. (2021) · Scientific Reports
Monoclonal and Polyclonal Antibodies Researchvaccines and immunoinformatics approaches
Cited by 144
- Verified
Anti-GPRC5D/CD3 Bispecific T-Cell–Redirecting Antibody for the Treatment of Multiple Myeloma
Kodama, T., Kochi, Y., Nakai, W., Mizuno, H., Baba, T., Habu, K., Sawada, N., Tsunoda, H., Shima, T., Miyawaki, K., et al. (2019) · Molecular Cancer Therapeutics
Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research
Cited by 80
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free